A Phase II, Randomised, Multi-Centre Study of Cabazitaxel Versus Abiraterone or Enzalutamide in Poor Prognosis-Metastatic Castration-Resistant Prostate Cancer

Project: Research

NMA Reference Number: HREC/16/MonH/165
Monash Health HREC Ref: 16-266A

Status	Active
Effective start/end date	4/01/19 → 3/01/24